Logo do repositório
 
Publicação

Prognostic role and clinicopathological features of SMAD4 gene mutation in pancreatic cancer: a systematic review and meta-analysis

2026-01-02Artigo de investigação Acesso aberto
Ver registo simples
dc.contributor.authorRodrigues, Tânia
dc.contributor.authorMartins, João Paulo
dc.contributor.authorAlbuquerque, Joana
dc.contributor.authorCardoso, Joana
dc.contributor.authorCoelho, José Luís Passos
dc.contributor.authorOliveira Martins, João Paulo
dc.date.accessioned2026-07-14T09:58:06Z
dc.date.available2026-07-14T09:58:06Z
dc.date.issued2026-01-02
dc.description.abstractThe prognostic value of SMAD4 in pancreatic cancer has been evaluated in several studies. However, the conclusions remain controversial. Therefore, we aimed to evaluate the prognostic value of the SMAD4 gene in pancreatic cancer to aid in the design of therapeutic strategies. This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria and the proposed methodology was registered on PROSPERO. An electronic search was made in MEDLINE (via PubMed), Web of Science and Google Scholar to identify all relevant studies. Eligible studies were those written in English including patients with Pancreatic Ductal Adenocarcinoma (PDAC), who underwent pancreatic surgery with curative intent and provided data on SMAD4 gene status or SMAD4 protein expression and its association to prognosis, measured by overall survival (OS). The effect measure of interest was the hazard ratio (HR) for OS between PDAC with or without SMDA4 mutations. A total of 24 studies on SMAD4, with 4340 samples, were included in this systematic review and meta-analysis. Our pooled results demonstrated that patients with tumours with SMAD4 alteration had significantly worse prognosis for OS (HR= 1.43, 95% CI = 1.17–1.76, p-value = 0.002). This systematic review and meta-analysis support the use of driver mutations in the SMAD4 gene as a prognostic marker for pancreatic cancer.eng
dc.description.sponsorshipHospital da Luz Learning Health under the project LH.INV.F29010
dc.identifier.citationRodrigues, T., Albuquerque, J., Cardoso, J., Sousa-Ferreira, I., Martins, J. P., & Coelho, J. L. P. (2026). Prognostic role and clinicopathological features of SMAD4 gene mutation in pancreatic cancer: A systematic review and meta-analysis. Cancer Treatment and Research Communications, 46, 101091. https://doi.org/10.1016/j.ctarc.2025.101091
dc.identifier.doi10.1016/j.ctarc.2025.101091
dc.identifier.eissn2468-2942
dc.identifier.urihttp://hdl.handle.net/10400.22/32590
dc.language.isoeng
dc.peerreviewedyes
dc.publisherElsevier
dc.relation00006/ 2025 and UID/PRR/00006/2025
dc.relation.hasversionhttps://www.sciencedirect.com/science/article/pii/S2468294225002266?via%3Dihub
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectPancreatic cancer (PDAC)
dc.subjectSMAD4 gene
dc.subjectSMAD4 protein
dc.subjectPrognostic
dc.subjectMutation
dc.subjectImmunohistochemistry
dc.titlePrognostic role and clinicopathological features of SMAD4 gene mutation in pancreatic cancer: a systematic review and meta-analysispor
dc.typeresearch article
dspace.entity.typePublication
oaire.citation.titleCancer Treatment and Research Communications
oaire.citation.volume46
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameOliveira Martins
person.givenNameJoão Paulo
person.identifier955929
person.identifier.ciencia-id6913-C065-48FF
person.identifier.orcid0000-0002-0474-1397
person.identifier.scopus-author-id55838096100
relation.isAuthorOfPublication9d1f7388-bb3e-4f1d-bf41-08a589b1d6a8
relation.isAuthorOfPublication.latestForDiscovery9d1f7388-bb3e-4f1d-bf41-08a589b1d6a8

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
ART_João Paulo Martins1.pdf
Tamanho:
2.25 MB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
4.03 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

ESS - BBB - Artigos